Prostate organoid research techniques and methods: three-dimensional (3D) culture, spin-down, dimpled parafilm and fusion method
JoVE will publish text articles after the peer review, which on average takes two months after the manuscript submission. We will film and add corresponding videos to our website when laboratories and facilities in affected areas reopen.
University of California San Diego
Dr. Sanghee Lee received her PhD from the Department of Urology and Cellular and Molecular Biology Program at the...
University of California San Diego
Dr. Jamieson is a translational scientist in Urologic Oncology, in the Department of Urology, University of California,...
Organoids are three-dimensional (3D) ex vivo cellular structures that are believed to recapitulate and maintain the in vivo conditions of cellular viability and responsiveness to therapeutic drugs. Matrigel or collagen have been utilized as an extracellular matrix to enable patient-derived cells to form 3D/organoids including cyst-like structures and spheroids. 3D cultured organoids are considered to be excellent models to understand the mechanisms of tumorigenesis and to determine the effects of anticancer agents. Therefore, methods have been developed for a range of cancers such as brain, breast, lung and prostate, among others. Prostate, however, is somewhat unique in that current methods for culturing organoids have a lower success rate than for other cancers. Difficulty in establishing prostate organoid cultures may be driven in part by tumorigenic heterogeneity. Most prostate organoids are derived from patient-derived xenografts (PDXs) and are genomically representative of the patient’s prostate cancer. Therefore, PDX organoids models are invaluable for studying down-stream signaling of target molecules and the effects of anti-cancer agent treatment. Several groups have developed modified protocols that are optimized for their experimental objectives. The goal of this collection is to (1) provide several examples of optimized culture condition for patient-derived prostate cancer 3D organoids, (2) introduce follow-up methodologies for single cell methods such as RNA-FISH and flow cytometry, (3) share meticulous details of immunohistochemistry (IHC)/ immunofluorescent (IF) technique specific for organoids and (4) differential criteria to determine the effects of drug treatment on organoids.
1Molecular Biology Interdepartmental Program, University of California, Los Angeles, 2Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, 3Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, 4Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, 5Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 6Molecular Biology Institute, University of California, Los Angeles
1Department of Urology, University of California, San Diego, 2Moores Cancer Center, University of California, San Diego, 3Department of Medicine, University of California, San Diego, 4Department of Radiation Oncology, University of California, Los Angeles, 5Department of Orthopedic Surgery, University of California, San Diego
1Department of Urology, College of Medicine, University of Illinois at Chicago, 2Department of Pathology, College of Medicine, University of Illinois at Chicago, 3University of Illinois Cancer Center, College of Medicine, University of Illinois at Chicago